98%
921
2 minutes
20
Alzheimer's disease is pathologically characterized by the presence of senile plaques and neurofibrillary tangles in the central nervous system. Amyloid β-protein is toxic to neurons and induces phosphorylation of Tau protein, which accumulates in paired helical filaments and leads to the formation of neurofibrillary tangles. This study is focused on the Wnt/β-catenin pathway influence on Tau phosphorylation and the distribution of microtubules and neurofilaments in adrenal pheochromocytoma cells. It was found that neurofilament heavy polypeptide and microtubule-associated protein-2 aggregated after treatment with Aβ₁₋₄₂. Treatment with Wnt5a reduced this aggregation, while Dickkopf-1 treatment promoted microtubule and neurofilament aggregation. Furthermore, Tau phosphorylation at Ser396, Ser422, and Ser199 was significantly reduced after Wnt5a treatment, whereas Dickkopf-1 increased the level of phosphorylation. These results suggest that the Wnt/β-catenin pathway influences the distribution of microtubules and neurofilaments, possibly by modulating the phosphorylation of Tau protein in adrenal pheochromocytoma cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.31083/j.jin.2019.03.168 | DOI Listing |
Lab Chip
September 2025
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA.
Traumatic brain injuries (TBIs) are a risk factor for Alzheimer's disease (AD), and share several important pathological features including the development of neurofibrillary tangles (NFT) of tau protein. While this association is well established, the underlying pathogenesis is poorly defined and current treatment options remain limited, necessitating novel methods and approaches. In response we developed "TBI-on-a-chip", an trauma model utilizing murine cortical networks on microelectrode arrays (MEAs), capable of reproducing clinically relevant impact injuries while providing simultaneous morphological and electrophysiological readout.
View Article and Find Full Text PDFJ Alzheimers Dis
September 2025
IRCCS Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy.
The "biological view" of Alzheimer's disease (AD) focuses on the role of plaques and tangles and excludes syndromes from the disease definition. However, cognitive syndromes are fundamental aspects of AD and are the ultimate target of treatments. Accordingly, the study of cognitive syndromes should remain a major goal of AD research.
View Article and Find Full Text PDFPsychogeriatrics
September 2025
Clinical Neurosciences and Mental Health Department, Faculty of Medicine of Porto University, Porto, Portugal.
The dopaminergic system may be at the base of some neurobehavioral symptoms, as apathy and depression, and extrapyramidal symptoms, often seen in Alzheimer's disease patients. It can also have an impact on cognitive decline, as extrapyramidal symptoms, classically linked with dopamine dysfunction, are associated with increased risk of cognitive impairment and Alzheimer's disease progression. We review the knowledge of the dopaminergic system, emphasizing changes in Alzheimer's disease.
View Article and Find Full Text PDFACS Sens
September 2025
Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences, Nanning, Guangxi 530021, China.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily characterized by cognitive decline and behavioral impairments, typically manifesting in the elderly and presenile population. With the rapid global aging trend, early diagnosis and treatment of AD have become increasingly urgent research priorities. The primary pathological features of AD include excessive accumulation of β-amyloid (Aβ) plaques, the formation of neurofibrillary tangles, and neuronal loss.
View Article and Find Full Text PDFJ Integr Neurosci
August 2025
CIBA Center for Advanced Biomedical Research, School of Medicine, Autonomous University of Queretaro, 76010 Querétaro, México.
Background: Neurofibrillary tangles, composed of hyperphosphorylated tau, have been implicated in the cognitive impairments observed in Alzheimer's disease. While the precise mechanism remains elusive, cognitive deficits in Alzheimer's disease have been associated with disrupted brain network activity. To investigate this mechanism, researchers have developed several tau transgenic models.
View Article and Find Full Text PDF